Home › Chronic Myelomonocytic Leukemia › Texas › Houston
Chronic Myelomonocytic Leukemia clinical trials in Houston, TX
16 studies for Chronic Myelomonocytic Leukemia are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RecruitingPhase 2Healthy volunteers welcome
- MD Anderson Cancer Center, Houston
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
RecruitingPhase 2
- MD Anderson Cancer Center, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
RecruitingPhase 2/3Healthy volunteers welcome
- M D Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RecruitingPhase 1/2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RecruitingPhase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
RecruitingPhase 1
- M D Anderson Cancer Center, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- MD Anderson Cancer Center, Houston
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
RecruitingPhase 1/2
- M D Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- MD Anderson, Houston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Chronic Myelomonocytic Leukemia trials in other cities
- Seattle, WA10 studies
- Boston, MA7 studies
- Mountain View, CA6 studies
- Baldwin Park, CA6 studies
- New York City, NY6 studies
- Rochester, MN6 studies
- Durham, NC5 studies
- Tampa, FL4 studies
- Birmingham, AL4 studies
- Columbus, OH4 studies
- Miami, FL4 studies
- Atlanta, GA4 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)122 studies
- Metastatic Cancer104 studies
- Colorectal Cancer103 studies
- Ovarian Cancer90 studies
- Acute Myeloid Leukemia86 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer69 studies
- Pancreatic Cancer62 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.